Alental, 20 pcs., 100 mg, film-coated tablets
The simultaneous use of Alental® and other NSAIDs, including selective COX-2 inhibitors, should be avoided.
Adverse events can be minimized by using the lowest effective dose and reducing the duration of treatment needed to control symptoms.
Effect on the gastrointestinal tract
Bleeding, ulceration or perforation of the gastrointestinal tract with a fatal outcome was observed when taking any NSAIDs during any period of treatment, as in the presence of corresponding symptoms and a history of serious gastrointestinal diseases (including gastric and duodenal ulcers, Crohn's disease, ulcerative colitis), and without them.
The risk of bleeding, ulceration, and gastrointestinal perforation increases with increasing doses of NSAIDs in patients with a history of peptic ulcer, especially if it was accompanied by bleeding or perforation, and in elderly patients. These patients should take the minimum effective dose of the drug. They require combination therapy with protective drugs (for example, misoprostol or proton pump inhibitors). Such treatment is necessary for patients who take small doses of acetylsalicylic acid or other drugs that negatively affect the gastrointestinal tract.
Patients with gastrointestinal diseases, incl. elderly should report any unusual gastrointestinal symptoms (especially bleeding), incl. when taking the drug for the first time. Particular caution should be exercised in patients concomitantly taking drugs that may increase the risk of bleeding or ulceration, such as systemic corticosteroids, anticoagulants (such as warfarin), SSRIs or antiplatelet agents (such as acetylsalicylic acid). If gastrointestinal bleeding or ulcers occur, treatment with Alental® should be discontinued.
Effect on the cardiovascular system and central nervous system
Patients with hypertension and/or mild to moderate congestive heart failure require appropriate monitoring because Taking NSAIDs (particularly in high doses with long-term use) may not significantly increase the risk of arterial thrombosis (for example, myocardial infarction or stroke). There is no reliable data on the absence of this risk when taking aceclofenac.
Patients with uncontrolled arterial hypertension, CHF, established coronary artery disease, atherosclerosis of peripheral arteries and/or cerebrovascular accident should be careful when taking Alental®. Also, before the first dose, caution should be exercised in patients with risk factors for cardiovascular disease (for example, hypertension, hyperlipidemia, diabetes mellitus, smoking).
Effect on the liver and kidneys
Taking NSAIDs can cause a dose-dependent decrease in PG formation and acute renal failure. The importance of PG in ensuring renal blood flow should be taken into account when using the drug in patients with impaired cardiac, renal or hepatic function, receiving diuretics, or after surgery, as well as in elderly patients.
Caution should be exercised when prescribing the drug to patients with mild or moderate impairment of liver and kidney function, as well as patients with other conditions predisposing to fluid retention in the body. In these patients, NSAIDs may cause renal dysfunction and fluid retention. Patients taking diuretics and those at increased risk of hypovolemia should also be careful when taking Alental®. It is necessary to prescribe the minimum effective dose and regular medical monitoring of kidney function. Adverse renal events usually resolve after discontinuation of aceclofenac.
Aceclofenac should be discontinued if changes in liver function tests persist or worsen, clinical signs or symptoms of liver disease develop, or other manifestations (eosinophilia, rash) occur. Hepatitis can develop without prodromal symptoms.
The use of NSAIDs in patients with hepatic porphyria may precipitate an attack.
Hypersensitivity and skin reactions
Like other NSAIDs, the drug may cause allergic reactions, including anaphylactic/anaphylactoid reactions, even if the drug is taken for the first time. Severe skin reactions (some of which can be fatal), including exfoliative dermatitis, Stevens-Johnson syndrome and toxic epidermal necrolysis, have been very rare after taking NSAIDs.
The highest risk of these reactions occurs during the 1st month of taking the drug. If skin rash, damage to the oral mucosa or other signs of hypersensitivity occur, you should stop taking Alental®.
In some cases, chickenpox can cause skin and soft tissue infections. At present, the role of NSAIDs in worsening the course of these infections cannot be ruled out. Therefore, you should avoid taking Alental® for chickenpox.
Hematological disorders
Aceclofenac may cause reversible inhibition of platelet aggregation.
Respiratory system disorders
Caution should be exercised when using the drug in patients with a history of bronchial asthma or current bronchial asthma, because taking NSAIDs may trigger the development of sudden bronchospasm in such patients.
Elderly patients
Caution should be exercised when using the drug in elderly patients, because they are more likely to experience side effects (especially bleeding and gastrointestinal perforation) when taking NSAIDs. Complications can be fatal. Also, older patients are more likely to suffer from kidney, liver, or cardiovascular diseases.
Long-term use
All patients receiving long-term treatment with NSAIDs should be closely monitored (eg, complete blood count, liver function tests, and renal function tests).
Impact on the ability to drive vehicles and operate machinery.
You should refrain from driving vehicles and engaging in other potentially hazardous activities that require increased concentration and speed of psychomotor reactions, because The drug may cause dizziness and other side effects that may affect these abilities.
Alental®
The simultaneous use of Alental® and other NSAIDs should be avoided. including selective cyclooxygenase-2 (COX-2) inhibitors.
Adverse events can be minimized by using the lowest effective dose and reducing the duration of treatment necessary to control symptoms.
Effect on the gastrointestinal tract
Bleeding, ulcers or perforation of the gastrointestinal tract with a fatal outcome were observed when taking any NSAIDs during any period of treatment, both in the presence of corresponding symptoms and a history of serious gastrointestinal diseases (peptic ulcer of the stomach and duodenum, Crohn's disease, ulcerative colitis, etc.), and and without them.
The risk of bleeding, ulceration, and gastrointestinal perforation increases with increasing doses of NSAIDs in patients with a history of peptic ulcers, especially those accompanied by bleeding or perforation, and in elderly patients. These patients should take the minimum effective dose of the drug. They require combination therapy with protective drugs (for example, misoprostol or proton pump inhibitors). Such treatment is necessary for patients who take small doses of acetylsalicylic acid or other drugs that negatively affect the gastrointestinal tract.
Patients with gastrointestinal diseases, including the elderly, should report any unusual gastrointestinal symptoms (especially bleeding), including when initially taking the drug. Particular caution should be exercised in patients concomitantly taking drugs that may increase the risk of bleeding or ulceration, such as systemic corticosteroids, anticoagulants (such as warfarin), selective serotonin reuptake inhibitors, or antiplatelet agents (such as acetylsalicylic acid).
If gastrointestinal bleeding or ulcers occur, treatment with Alental® should be discontinued.
Effects on the cardiovascular and central nervous system
Patients with arterial hypertension and/or mild to moderate congestive heart failure require appropriate monitoring, since taking NSAIDs (particularly in high doses with long-term use) may not significantly increase the risk of arterial thrombosis (for example, myocardial infarction or stroke). There is no reliable data on the absence of this risk when taking aceclofenac.
Patients with uncontrolled arterial hypertension, chronic heart failure, established coronary heart disease, atherosclerosis of peripheral arteries and/or cerebrovascular accident should be careful when taking Alental®. Also, before the first dose, caution should be exercised in patients with risk factors for the cardiovascular system (for example, hypertension, hyperlipidemia, diabetes mellitus, smoking).
Effect on the liver and kidneys
Taking NSAIDs can cause a dose-dependent decrease in prostaglandin formation and acute renal failure. The importance of prostaglandins in maintaining renal blood flow should be considered when taking the drug in patients with impaired cardiac, renal or hepatic function, in patients receiving diuretics or in patients after surgery, as well as in elderly patients.
Caution should be exercised when prescribing the drug to patients with mild or moderate impairment of liver and kidney function, as well as patients with other conditions predisposing to fluid retention in the body. In these patients, NSAIDs may cause renal dysfunction and fluid retention. Patients taking diuretics and those at increased risk of hypovolemia should also be careful when taking Alental®. It is necessary to prescribe the minimum effective dose and regular medical monitoring of night function. Adverse renal events usually resolve after discontinuation of aceclofenac.
Aceclofenac should be discontinued if changes in liver function tests persist or worsen, clinical signs or symptoms of liver disease develop, or other manifestations (eosinophilia, rash) occur. Hepatitis can develop without prodromal symptoms.
The use of NSAIDs in patients with hepatic porphyria may precipitate an attack.
Hypersensitivity and skin reactions
Like other NSAIDs, the drug may cause allergic reactions, including anaphylactic/anaphylactoid reactions, even if the drug is taken for the first time. Severe skin reactions (some of which can be fatal), including exfoliative dermatitis, Stevens-Johnson syndrome and toxic epidermal necrolysis, have been observed very rarely after taking NSAIDs.
The highest risk of these reactions occurs during the first month of taking the drug. If skin rash, damage to the oral mucosa or other signs of hypersensitivity occur, you should stop taking Alental®.
In some cases, chickenpox can cause skin and soft tissue infections.
At present, the role of NSAIDs in worsening the course of these infections cannot be ruled out. Therefore, you should avoid taking Alental® for chickenpox.
Hematological disorders
Aceclofenac may cause reversible inhibition of platelet aggregation.
Respiratory system disorders
Caution should be exercised when taking the drug to patients with a history of bronchial asthma or current bronchial asthma, since taking NSAIDs may trigger the development of sudden bronchospasm in such patients.
Elderly patients
Caution should be exercised when taking the drug in elderly patients, as they are more likely to experience side effects (especially bleeding and perforation of the gastrointestinal tract) when taking NSAIDs. Complications can be fatal. Older patients are also more likely to suffer from kidney, liver, or cardiovascular diseases.
Long-term use
All patients receiving long-term treatment with NSAIDs should be closely monitored (eg, complete blood count, liver function tests, and renal function tests).
Alenthal
Concomitant use of Alental and other NSAIDs, including selective cyclooxygenase-2 (COX-2) inhibitors, should be avoided.
Adverse events can be minimized by using the lowest effective dose and reducing the duration of treatment needed to control symptoms.
Effect on the gastrointestinal tract
Bleeding, ulcers or perforation of the gastrointestinal tract with a fatal outcome were observed when taking any NSAIDs during any period of treatment, both in the presence of corresponding symptoms and a history of serious gastrointestinal diseases (peptic ulcer of the stomach and duodenum, Crohn's disease, ulcerative colitis, etc.), and and without them.
The risk of bleeding, ulceration, and gastrointestinal perforation increases with increasing doses of NSAIDs in patients with a history of peptic ulcers, especially those accompanied by bleeding or perforation, and in elderly patients. Such patients should be prescribed the minimum effective dose of aceclofenac. Also, when treating these groups of patients and patients who require concomitant use of acetylsalicylic acid in low doses or other drugs that may increase the risk of gastrointestinal complications, the need for combination therapy with protective drugs (for example, misoprostol or proton pump inhibitors) should be considered. ).
Patients with gastrointestinal diseases, including elderly patients, should report any unusual gastrointestinal symptoms (especially bleeding), including when initially taking Alental. Particular caution should be exercised in patients concomitantly taking drugs that may increase the risk of bleeding or ulceration, such as systemic corticosteroids, anticoagulants (such as warfarin), selective serotonin reuptake inhibitors, or antiplatelet agents (such as acetylsalicylic acid).
If gastrointestinal bleeding or ulcers occur, treatment with Alental should be discontinued.
Effects on the cardiovascular and central nervous system
Patients with arterial hypertension and/or mild to moderate congestive heart failure require appropriate monitoring, since taking NSAIDs (particularly in high doses with long-term use) may not significantly increase the risk of arterial thrombosis (for example, myocardial infarction or stroke). There is no reliable data on the absence of such a risk when taking aceclofenac.
Patients with uncontrolled arterial hypertension, chronic heart failure, established coronary heart disease, atherosclerosis of peripheral arteries and/or cerebrovascular accident should be careful when taking Alental. Also, before taking the drug for the first time, caution should be exercised in patients with risk factors for the cardiovascular system (for example, hypertension, hyperlipidemia, diabetes mellitus, smoking).
Effect on the liver and kidneys
Taking NSAIDs can cause a dose-dependent decrease in prostaglandin formation and acute renal failure. The importance of prostaglandins in maintaining renal blood flow should be considered when taking Alental in patients with impaired cardiac, renal or hepatic function, in patients receiving diuretics, in patients after surgery, as well as in elderly patients.
Caution should be exercised when prescribing Alental to patients with mild or moderate hepatic and renal dysfunction, as well as to patients with other conditions predisposing to fluid retention in the body. In such patients, NSAIDs can lead to impaired renal function and fluid retention. Patients taking diuretics and those at increased risk of hypovolemia should also be careful when taking the drug. It is necessary to prescribe the minimum effective dose and regular medical monitoring of renal function. Adverse renal events usually resolve after discontinuation of aceclofenac.
Aceclofenac should be discontinued if changes in liver function tests persist or worsen, clinical signs or symptoms of liver disease develop, or other manifestations (eosinophilia, rash) occur. Hepatitis can develop without prodromal symptoms.
The use of NSAIDs in patients with hepatic porphyria may precipitate an attack.
Hypersensitivity and skin reactions
Like other NSAIDs, aceclofenac can cause allergic reactions, including anaphylactic/anaphylactoid reactions, even when taken for the first time. Severe skin reactions (some of which can be fatal), including exfoliative dermatitis, Stevens-Johnson syndrome and toxic epidermal necrolysis, have been observed very rarely after taking NSAIDs. The highest risk of these reactions occurs during the first month of taking aceclofenac. If skin rash, damage to the oral mucosa, or other signs of hypersensitivity occur, you should stop taking Alental.
In some cases, chickenpox can cause skin and soft tissue infections. At present, the role of NSAIDs in worsening the course of these infections cannot be ruled out. Therefore, you should avoid taking Alentalf if you have chickenpox.
Hematological disorders
Aceclofenac may cause reversible inhibition of platelet aggregation.
Respiratory system disorders
Caution should be exercised when taking the drug to patients with a history of bronchial asthma or current bronchial asthma, since taking NSAIDs may trigger the development of sudden bronchospasm in such patients.
Elderly patients
Caution should be exercised when taking Alental in elderly patients, as they are more likely to experience side effects (especially bleeding and gastrointestinal perforation) when taking NSAIDs. Complications can be fatal. Older patients are also more likely to suffer from kidney, liver, or cardiovascular diseases.
Long-term use
All patients receiving long-term treatment with NSAIDs should be closely monitored (eg, complete blood count, liver function tests, and renal function tests).
Impact on the ability to drive vehicles and machinery
You should refrain from driving vehicles and engaging in other potentially hazardous activities that require increased concentration and speed of psychomotor reactions, as the drug may cause dizziness and other side effects that may affect these abilities.
Alental tab film 100mg 60 pcs vertex
The simultaneous use of Alental® and other NSAIDs, including selective cyclooxygenase-2 (COX-2) inhibitors, should be avoided. Adverse events can be minimized by using the lowest effective dose and reducing the duration of treatment needed to control symptoms.
Effect on the gastrointestinal tract Bleeding, ulcer or perforation of the gastrointestinal tract with a fatal outcome was observed when taking any NSAIDs during any period of treatment, both in the presence of corresponding symptoms and in the presence of a history of serious gastrointestinal diseases (peptic ulcer of the stomach and duodenum, Crohn's disease, ulcerative colitis, etc. ), and without them.
The risk of bleeding, ulceration, and gastrointestinal perforation increases with increasing doses of NSAIDs in patients with a history of peptic ulcers, especially those accompanied by bleeding or perforation, and in elderly patients. Such patients should be prescribed the minimum effective dose of aceclofenac. Also, when treating these groups of patients and patients who require concomitant use of acetylsalicylic acid in low doses or other drugs that may increase the risk of gastrointestinal complications, the need for combination therapy with protective drugs (for example, misoprostol or proton pump inhibitors) should be considered. ).
Patients with gastrointestinal diseases, including elderly patients, should report any unusual gastrointestinal symptoms (especially bleeding), including when initially taking Alental®. Particular caution should be exercised in patients concomitantly taking drugs that may increase the risk of bleeding or ulceration, such as systemic corticosteroids, anticoagulants (such as warfarin), selective serotonin reuptake inhibitors, or antiplatelet agents (such as acetylsalicylic acid).
If gastrointestinal bleeding or ulcers occur, treatment with Alental® should be discontinued.
Effects on the cardiovascular and central nervous system
Patients with arterial hypertension and/or mild to moderate congestive heart failure require appropriate monitoring, since taking NSAIDs (particularly in high doses with long-term use) may not significantly increase the risk of arterial thrombosis (for example, myocardial infarction or stroke). There is no reliable data on the absence of such a risk when taking aceclofenac.
Patients with uncontrolled arterial hypertension, chronic heart failure, established coronary heart disease, atherosclerosis of peripheral arteries and/or cerebrovascular accident should be careful when taking Alental®. Also, before taking Alental® for the first time, caution should be exercised in patients with risk factors for the cardiovascular system (for example, hypertension, hyperlipidemia, diabetes mellitus, smoking).
Effect on the liver and kidneys
Taking NSAIDs can cause a dose-dependent decrease in prostaglandin formation and acute renal failure. The importance of prostaglandins for renal blood flow should be taken into account when taking Alental® in patients with impaired cardiac, renal or hepatic function, in patients receiving diuretics, in patients after surgery, as well as in elderly patients.
Caution should be exercised when prescribing Alental® to patients with mild or moderate hepatic and renal dysfunction, as well as to patients with other conditions predisposing to fluid retention in the body. In such patients, NSAIDs can lead to impaired renal function and fluid retention. Patients taking diuretics and those at increased risk of hypovolemia should also use caution when taking Alental®. It is necessary to prescribe the minimum effective dose and regular medical monitoring of renal function. Adverse renal events usually resolve after discontinuation of aceclofenac.
Aceclofenac should be discontinued if changes in liver function tests persist or worsen, clinical signs or symptoms of liver disease develop, or other manifestations (eosinophilia, rash) occur. Hepatitis can develop without prodromal symptoms.
The use of NSAIDs in patients with hepatic porphyria may precipitate an attack.
Hypersensitivity and skin reactions
Like other NSAIDs, aceclofenac can cause allergic reactions, including anaphylactic/anaphylactoid reactions, even when taken for the first time. Severe skin reactions (some of which can be fatal), including exfoliative dermatitis, Stevens-Johnson syndrome and toxic epidermal necrolysis, have been observed very rarely after taking NSAIDs. The highest risk of these reactions occurs during the first month of taking aceclofenac. If skin rash, damage to the oral mucosa or other signs of hypersensitivity occur, you should stop taking Alental®.
In some cases, chickenpox can cause skin and soft tissue infections. At present, the role of NSAIDs in worsening the course of these infections cannot be ruled out. Therefore, you should avoid taking Alental® for chickenpox.
Hematological disorders
Aceclofenac may cause reversible inhibition of platelet aggregation.
Respiratory system disorders
Caution should be exercised when taking Alental® to patients with a history of bronchial asthma or current bronchial asthma, since taking NSAIDs may trigger the development of sudden bronchospasm in such patients.
Elderly patients
Caution should be exercised when taking Alental® in elderly patients, as they are more likely to experience side effects (especially bleeding and gastrointestinal perforation) when taking NSAIDs. Complications can be fatal. Older patients are also more likely to suffer from kidney, liver, or cardiovascular diseases.
Long-term use
All patients receiving long-term treatment with NSAIDs should be closely monitored (eg, complete blood count, liver function tests, and renal function tests).
Impact on the ability to drive vehicles and machinery
You should refrain from driving vehicles and engaging in other potentially hazardous activities that require increased concentration and speed of psychomotor reactions, as the drug may cause dizziness and other side effects that may affect these abilities.
